Mangoceuticals (NASDAQ:MGRX – Get Free Report) is one of 19 publicly-traded companies in the “Miscellaneous health & allied services, not elsewhere classified” industry, but how does it compare to its rivals? We will compare Mangoceuticals to related companies based on the strength of its dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.
Insider & Institutional Ownership
56.7% of Mangoceuticals shares are held by institutional investors. Comparatively, 61.8% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are held by institutional investors. 39.3% of Mangoceuticals shares are held by company insiders. Comparatively, 27.3% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Mangoceuticals and its rivals top-line revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Mangoceuticals | $866,792.00 | -$9.21 million | -0.38 |
Mangoceuticals Competitors | $2.39 billion | $82.32 million | 15.54 |
Analyst Recommendations
This is a summary of current recommendations for Mangoceuticals and its rivals, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Mangoceuticals | 0 | 0 | 0 | 0 | N/A |
Mangoceuticals Competitors | 36 | 288 | 416 | 148 | 2.76 |
As a group, “Miscellaneous health & allied services, not elsewhere classified” companies have a potential upside of 50.46%. Given Mangoceuticals’ rivals higher possible upside, analysts plainly believe Mangoceuticals has less favorable growth aspects than its rivals.
Volatility & Risk
Mangoceuticals has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500. Comparatively, Mangoceuticals’ rivals have a beta of 4.14, indicating that their average stock price is 314% more volatile than the S&P 500.
Profitability
This table compares Mangoceuticals and its rivals’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Mangoceuticals | -1,053.93% | -243.34% | -200.73% |
Mangoceuticals Competitors | -816.62% | -48.14% | -36.60% |
Summary
Mangoceuticals rivals beat Mangoceuticals on 9 of the 10 factors compared.
About Mangoceuticals
Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
Receive News & Ratings for Mangoceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mangoceuticals and related companies with MarketBeat.com's FREE daily email newsletter.